Table 1.
Comparative analysis of biological features of SARS-CoV and SARS-CoV-2.
| Features | SARS-CoV | SARS-CoV-2 | Reference |
|---|---|---|---|
| Emergence date | November 2002 | December 2019 | [37], [79], [80], [81] |
| Area of emergence | Guangdong, China | Wuhan, China | |
| Date of fully controlled | July 2003 | Not controlled yet | |
| Key hosts | Bat, palm civets and Raccon dogs | Bat | [22], [82], [83] |
| Number of countries infected | 26 | 109 | [84] |
| Entry receptor in humans | ACE2 receptor | ACE2 receptor | [22], [55], [85] |
| Sign and symptoms | fever, malaise, myalgia, headache, diarrhoea, shivering, cough and shortness of breath | Cough, fever and shortness of breath | [12], [23], [85] |
| Disease caused | SARS, ARDS | SARS, COVID-19 | [85], [86] |
| Total infected patients | 8098 | 123882 | [84] |
| Total recovered patients | 7322 | 67051 | |
| Total died patients | 776 (9.6% mortality rate) | 4473 (3.61% mortality rate) |